These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 809716)

  • 21. Trypanosoma cruzi: peripheral blood monocytes and heart macrophages in the resistance to acute experimental infection in rats.
    Melo RC; Machado CR
    Exp Parasitol; 2001 Jan; 97(1):15-23. PubMed ID: 11207110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The protective effect of the 4-5S immune RNA against Trypanosoma cruzi infection in mice.
    Bertolini MC; De Lucca FL
    Trop Med Parasitol; 1985 Sep; 36(3):131-4. PubMed ID: 2417303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Marked increase in Ia-bearing macrophages during Trypanosoma cruzi infection.
    Behbehani K; Pan SC; Unanue ER
    Clin Immunol Immunopathol; 1981 May; 19(2):190-5. PubMed ID: 6784986
    [No Abstract]   [Full Text] [Related]  

  • 24. Chagas cardiomyopathy (Trypanosoma cruzi): does prolactin play a role?
    Pearson RD
    Cytokine Growth Factor Rev; 2007; 18(3-4):209. PubMed ID: 17512239
    [No Abstract]   [Full Text] [Related]  

  • 25. Cellular immune response to common mycobacterial antigens in subjects seropositive for Trypanosoma cruzi.
    Bottasso OA; Ingledew N; Keni M; Morini J; Pividori JF; Rook GA; Stanford JL
    Lancet; 1994 Dec; 344(8936):1540-1. PubMed ID: 7983955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trypanosoma cruzi: the fate of bloodstream trypomastigote, amastigote, metacyclic trypomastigote and epimastigote forms in the peritoneal macrophages of immune and non-immune mice in vivo.
    Burger E; Lay WH; Hypolito LV; Fernandes JF
    Acta Trop; 1982 Jun; 39(2):111-22. PubMed ID: 6126093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Colony-stimulating factors in parasitic diseases.
    Reed SG
    Diagn Microbiol Infect Dis; 1990; 13(5):387-9. PubMed ID: 2126497
    [No Abstract]   [Full Text] [Related]  

  • 28. Adoptive transfer of protection against Trypanosoma cruzi with lymphocytes and macrophages.
    Burgess DE; Hanson WL
    Infect Immun; 1979 Sep; 25(3):838-43. PubMed ID: 115790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mammalian Target of Rapamycin Inhibition in
    Rojas Márquez JD; Ana Y; Baigorrí RE; Stempin CC; Cerban FM
    Front Immunol; 2018; 9():313. PubMed ID: 29515594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease.
    Barry MA; Wang Q; Jones KM; Heffernan MJ; Buhaya MH; Beaumier CM; Keegan BP; Zhan B; Dumonteil E; Bottazzi ME; Hotez PJ
    Hum Vaccin Immunother; 2016 Apr; 12(4):976-87. PubMed ID: 26890466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic control of the mechanisms of resistance against experimental Trypanosoma cruzi infection. I: Role of the macrophages in resistant and suceptible strains of mice.
    Pécora IL; Barcinski MA
    Rev Bras Biol; 1979 May; 39(2):445-50. PubMed ID: 119283
    [No Abstract]   [Full Text] [Related]  

  • 32. MIF-driven activation of macrophages induces killing of intracellular Trypanosoma cruzi dependent on endogenous production of tumor necrosis factor, nitric oxide and reactive oxygen species.
    Cutrullis RA; Petray PB; Corral RS
    Immunobiology; 2017 Feb; 222(2):423-431. PubMed ID: 27591076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trypanosoma cruzi: modification of macrophage function during infection.
    Nogueira N; Gordon S; Cohn Z
    J Exp Med; 1977 Jul; 146(1):157-71. PubMed ID: 327012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene Expression Profiling and Functional Characterization of Macrophages in Response to Circulatory Microparticles Produced during Trypanosoma cruzi Infection and Chagas Disease.
    Chowdhury IH; Koo SJ; Gupta S; Liang LY; Bahar B; Silla L; Nuñez-Burgos J; Barrientos N; Zago MP; Garg NJ
    J Innate Immun; 2017; 9(2):203-216. PubMed ID: 27902980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo administration of recombinant IFN-gamma induces macrophage activation, and prevents acute disease, immune suppression, and death in experimental Trypanosoma cruzi infections.
    Reed SG
    J Immunol; 1988 Jun; 140(12):4342-7. PubMed ID: 3131431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trypanosoma cruzi: induction of microbicidal activity in human mononuclear phagocytes.
    Nogueira N; Chaplan S; Reesink M; Tydings J; Cohn ZA
    J Immunol; 1982 May; 128(5):2142-6. PubMed ID: 6801131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance of mice immunized with irradiated and lyophilized stages of Trypanosoma cruzi to infections with metacyclics.
    Okanla EO; Stumpf JL; Dusanic DG
    Int J Parasitol; 1982 Aug; 12(4):251-6. PubMed ID: 6811465
    [No Abstract]   [Full Text] [Related]  

  • 38. Parasite-induced chronic inflammation is not exacerbated by immunotherapy before or during Trypanosoma cruzi Infection.
    Duthie MS; Kahn M; Zakayan A; White M; Kahn SJ
    Clin Vaccine Immunol; 2007 Aug; 14(8):1005-12. PubMed ID: 17538117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surface interactions between macrophages and Trypanosoma cruzi.
    Reed SG; Douglass TG; Speer CA
    Am J Trop Med Hyg; 1982 Jul; 31(4):723-9. PubMed ID: 7048947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The protective effect of non-immunologic granulomatous inflammation in Trypanosoma cruzi infection of mice.
    De Mesquita RP
    Rev Bras Biol; 1979 Mar; 39(1):99-102. PubMed ID: 111311
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.